Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Verenium today announce that they have entered into a definitive agreement under which DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of US$ 37 million. The transaction has been completed.
The acquisition includes Verenium's oilseed processing business and IP portfolio, licenses for certain food enzymes and access to biodiversity libraries that Verenium will create using proprietary technology. The 2012 sales of these businesses are estimated at about US$ 15 million, growing rapidly in the coming years.
The purchase by DSM of these assets fully supports DSM's strategy for its Nutrition cluster, "continued value growth", and strengthens and broadens DSM's enzymes business and capabilities. With the acquisition of these assets and licenses DSM will further strengthen its industrial biotech activities (e.g. in oilseed processing) and reinforce its food enzymes innovation pipeline.
Verenium is headquartered in San Diego (California, USA). It has developed a number of high-performance enzyme products and product candidates for use in industrial processes. Verenium's enzyme products minimize pollution by reducing or replacing harsh chemicals used in industrial processes while also enhancing yields in their customers' processes.
DSM acquired Verenium's oilseed processing business, including the R&D portfolio and partnership agreements. As part of the agreement, a number of Verenium employees will be offered to transfer to DSM. Verenium has developed Purifine® PLC, an enzyme that offers crop-based oil producers a sustainable way to improve yields as well as overall processing economics. The annual market growth for enzymes in the global crop-based oil market is expected to be about 50% in the coming years with the market potential estimated at more than USD 350 million.
DSM also acquired exclusive world-wide licenses to alpha-amylase and xylanaseenzymes within the food and beverage markets. The market size for food enzymes alone is more than USD 1.3 billion.
In addition, DSM will have access to the newly developed bio-diversity collection and library being created by Verenium. By extracting microbial DNA directly from collected samples the slow and often impossible task of culturing individual microbes in a laboratory is avoided. Utilizing ultra high-throughput screening technologies, Verenium mines its collection of billions of microbial genes in search of unique enzymes.
Stephan Tanda, Member of the DSM Managing Board and responsible for the Nutrition cluster, said: "This acquisition will broaden our enzymes business and fits very well in our strategy of continued value growth for our Nutrition cluster. It will also further support our leading industrial biotechnology position."
Hans-Christian Ambjerg, President DSM Food Specialties, said: "For DSM Food Specialties this acquisition is a great step in achieving our ambitious growth strategy as we expand our enzymes business beyond our current applications. We will be able to provide sustainable enzyme solutions to rapidly growing new segments for DSM such as oilseed processing."
Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of around €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.
